ArticleThe World Allergy Organization journal2026
Incidence and prevalence of hypereosinophilic syndrome in the United States: A retrospective claims database study.
Article in The World Allergy Organization journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Hypereosinophilic syndrome (HES) encompasses rare disorders characterized by persistent hypereosinophilia resulting in organ damage. This study assessed demographics, incidence, and prevalence of HES in the United States following the introduction of HES-specific International Classification of Diseases 10th revision, Clinical Modification (ICD-10-CM) codes in 2020. Methods: This retrospective analysis used data from patients with HES and ≥12 months of continuous insurance coverage between October 1, 2020, and June 30, 2024, from Optum's de-identified Clinformatics® Data Mart Database. Incidence rates were calculated from the number of new HES cases divided by total person-time at risk, and prevalence from the proportion of HES cases in the population during the study. Results: Overall, 695 and 1224 patients fulfilled the incident and prevalent HES case definition, respectively. The overall HES incidence rate (95% CI) was 2.01 (1.87-2.17) per 100,000 person-years, with fluctuations between 2021 and 2024. The overall HES prevalence (95% CI) was 5.32 (5.02-5.62) per 100,000 persons, with increases between 2020 and 2024. Incidence and prevalence increased with age, with an almost even female-to-male ratio (51:49). Conclusions: HES had low incidence and prevalence, with increasing prevalence from 2020 to 2024, indicating an increased recording and growing awareness of HES with ICD-10-CM codes usage.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.